Literature DB >> 9339937

The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis.

A J Comerota1, V Chouhan, R N Harada, L Sun, J Hosking, R Veermansunemi, A J Comerota1, D Schlappy, A K Rao.   

Abstract

BACKGROUND AND OBJECTIVES: Intermittent pneumatic compression (IPC) is an effective form of deep vein thrombosis prophylaxis for general surgery patients. The antithrombotic effect of IPC is thought to be the result of increased venous velocity and stimulation of endogenous fibrinolysis. However, the mechanism of enhanced fibrinolytic activity and the relative effects on normal and postthrombotic veins have not been defined. The purposes of this study are 1) to quantify changes in fibrinolytic activity with IPC; 2) to study the mechanism of fibrinolytic enhancement with IPC; and 3) to evaluate whether postthrombotic patients have the same capacity for fibrinolytic enhancement with IPC as do normal subjects.
METHODS: Twelve volunteers (6 normal and 6 postthrombotic) had 5 IPC devices applied for 120 minutes in random fashion, 1 per week x 5 weeks. The devices included single-chamber, sequential, foot, calf, and long-leg compression. Subjects had an indwelling antecubital venous cannula placed for blood drawn at baseline, 60, 120, and 180 minutes after IPC devices were applied. Global fibrinolytic activity (euglobulin fraction, fibrin plate assay), tissue plasminogen activator (tPA) antigen (Ag) and activity (Act), plasminogen activator inhibitor-1 (PAI-1) Ag and Act, alpha-2-antiplasmin-plasmin complexes, and von Willebrand factor (vWF) antigen were assayed.
RESULTS: A striking elevation in fibrinolytic activity was noted at 180 minutes with all devices in normal subjects and postthrombotic patients (p = 0.01-0.0001); however, baseline and stimulated fibrinolytic activity was attenuated in postthrombotic patients (<0.03). The tPA-Act increased only in normal subjects (3.8 +/- 1.9%) (p = 0.057), despite a decrease in plasma tPA-Ag, which was observed in both normal subjects (-12.4 +/- 3.8%) (p = 0.009) and patients (-17.2 +/- 3.1%) (p = 0.001). PAI-1-Ag decreased in both normal subjects (-13.4 +/- 3.8%) (p = 0.007) and patients (-12.0 +/- 3.1%) (p = 0.013) with a marked reduction in PAI-1-Act in both normal subjects (p = 0.003) and patients (p = 0.004). There were no changes in vWF, and alpha-2-antiplasmin-plasmin complexes increased only in postthrombotic patients (p = 0.021).
CONCLUSIONS: Stimulation of endogenous fibrinolytic activity occurs after IPC, both in normal subjects and postthrombotic patients; however, baseline and overall fibrinolytic response in postthrombotic patients is reduced. The mechanism of increased fibrinolytic activity is likely because of a reduction in PAI-1, with a resulting increase of tPA activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9339937      PMCID: PMC1191029          DOI: 10.1097/00000658-199709000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

2.  Alteration in fibrinolysis associated with surgery and venous thrombosis.

Authors:  A O Mansfield
Journal:  Br J Surg       Date:  1972-10       Impact factor: 6.939

Review 3.  Prostaglandin and thromboxane mediation of cardiopulmonary failure.

Authors:  H B Hechtman; W V Huval; M A Mathieson; L I Stemp; C R Valeri; D Shepro
Journal:  Surg Clin North Am       Date:  1983-04       Impact factor: 2.741

4.  Fibrinolytic response to surgery. Labile and stable patterns and their relevance to post-operative deep venous thrombosis.

Authors:  M T Knight; R Dawson; D G Melrose
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

5.  Effect of optimization of hemodynamics on fibrinolytic activity and antithrombotic efficacy of external pneumatic calf compression.

Authors:  E W Salzman; G P McManama; A H Shapiro; L K Robertson; A S Donovan; H W Blume; J Sweeney; R D Kamm; M C Johnson; P M Black
Journal:  Ann Surg       Date:  1987-11       Impact factor: 12.969

6.  Elevated levels of 6-keto-prostaglandin-F1a from a lower extremity during external pneumatic compression.

Authors:  D P Guyton; A Khayat; E A Husni; H Schreiber
Journal:  Surg Gynecol Obstet       Date:  1988-04

7.  Preoperative prediction of postoperative deep vein thrombosis.

Authors:  J K Clayton; J A Anderson; G P McNicol
Journal:  Br Med J       Date:  1976-10-16

8.  Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.

Authors:  G Nicoloso; J Hauert; E K Kruithof; G Van Melle; F Bachmann
Journal:  Thromb Haemost       Date:  1988-04-08       Impact factor: 5.249

9.  Relationship between postsurgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices.

Authors:  L Summaria; J A Caprini; R McMillan; J Sandesara; C A Axelrod; M E Mueller; J P Vagher; J Walenga; J Fareed
Journal:  Am Surg       Date:  1988-03       Impact factor: 0.688

10.  Pneumatic calf compression, fibrinolysis, and the prevention of deep venous thrombosis.

Authors:  T J Tarnay; P R Rohr; A G Davidson; M M Stevenson; E F Byars; G R Hopkins
Journal:  Surgery       Date:  1980-10       Impact factor: 3.982

View more
  27 in total

1.  Investigation of Blood Flow During Intermittent Pneumatic Compression and Proposal of a New Compression Protocol.

Authors:  Wonhee Lee; Jong Hyun Seo; Hyun Beom Kim; Seung Hyun Chung; Seung Hoon Lee; Kwang Gi Kim; Hyun Guy Kang
Journal:  Clin Appl Thromb Hemost       Date:  2016-12-18       Impact factor: 2.389

Review 2.  Safety in the operating theatre--a transition to systems-based care.

Authors:  Thomas G Weiser; Michael P Porter; Ronald V Maier
Journal:  Nat Rev Urol       Date:  2013-02-19       Impact factor: 14.432

3.  Provisional Matrix Deposition in Hemostasis and Venous Insufficiency: Tissue Preconditioning for Nonhealing Venous Ulcers.

Authors:  Tony J Parker; James A Broadbent; Jacqui A McGovern; Daniel A Broszczak; Christina N Parker; Zee Upton
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

4.  A combination of heparin and an intermittent pneumatic compression device may be more effective to prevent deep-vein thrombosis in the lower extremities after laparoscopic cholecystectomy.

Authors:  Y Okuda; T Kitajima; H Egawa; S Hamaguchi; S Yamaguchi; H Yamazaki; K Ido
Journal:  Surg Endosc       Date:  2002-02-08       Impact factor: 4.584

Review 5.  Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement.

Authors:  Jin Min Zhao; Mao Lin He; Zeng Ming Xiao; Ting Song Li; Hao Wu; Hua Jiang
Journal:  Cochrane Database Syst Rev       Date:  2014-12-22

Review 6.  Venous thromboembolism prophylaxis.

Authors:  Jonathan Laryea; Bradley Champagne
Journal:  Clin Colon Rectal Surg       Date:  2013-09

7.  Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.

Authors:  Mehmet Kurtoglu; Hakan Yanar; Yilmaz Bilsel; Recep Guloglu; Sevda Kizilirmak; Dincay Buyukkurt; Volkan Granit
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

Review 8.  Intermittent pneumatic compression in immobile patients.

Authors:  Hugo Partsch
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

9.  Evidence-based compression: prevention of stasis and deep vein thrombosis.

Authors:  Rhys J Morris; John P Woodcock
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

10.  Low-molecular-weight heparin and intermittent pneumatic compression for thromboprophylaxis in critical patients.

Authors:  Bing Wan; Hai-Yan Fu; Jiang-Tao Yin; Guo-Qing Ren
Journal:  Exp Ther Med       Date:  2015-10-13       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.